Several COVID-19 vaccinations are in development in the US and abroad.
The Pfizer-BioNTech COVID-19 vaccine, which received FDA Emergency Use Authorization December 11, 2020, demonstrates 95% effectiveness against COVID-19 beginning 28 days after the first dose. (A second dose is required 21 days after the first dose.)
NEW! August 23, 2021, the U.S. Food and Drug Administration approved the Pfizer-BioNTech Vaccine (which will be marketed as Comirnaty (koe-mir’-na-tee)) for individuals 16 years of age and older. The vaccine also continues to be available under emergency use authorization (EUA), including for individuals 12 through 15 years of age and for the administration of a third dose in certain immunocompromised individuals. Click here to read the FDA's press release.
The Moderna vaccine, which received Emergency Use Authorization on December 18th, 2020, demonstrates 94.1% effectiveness at preventing symptomatic cases of COVID-19.